Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinib

26 Mar 2022

Abstract excerpt

Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a non‐invasive in vitro next‐generation sequencing (NGS)‐based diagnostic, detects genomic alterations in plasma circulating tumour DNA (ctDNA). We evaluated the clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35338679
DOI: 10.1002/1878-0261.13214

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pre‐ and post‐treatment blood‐based genomic landscape of patients with ROS1 or NTRK fusion‐positive solid tumours treated with entrectinibPMID 35338679Read ↗

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.Semantic proximity Read ↗

Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2Semantic proximity Read ↗

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA.Semantic proximity Read ↗

Circulating DNA‐Based Sequencing Guided Anlotinib Therapy in Non‐Small Cell Lung CancerSemantic proximity Read ↗

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.Semantic proximity Read ↗

NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer typesSemantic proximity Read ↗

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNASemantic proximity Read ↗

Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.Semantic proximity Read ↗

Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.Semantic proximity Read ↗

Detection of circulating plasma tumour mutations in early stage triple negative breast cancer as an adjunct to pathological complete response assessmentSemantic proximity Read ↗

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.Semantic proximity Read ↗

Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.